Publication Name	World Journal of Hepatology
Manuscript ID	17205
Country	Italy

Received	2015-02-25 10:46
Peer-Review Started	2015-02-25 20:17
To Make the First Decision	2015-06-03 14:39
Return for Revision	2015-06-04 16:25
Revised	2015-06-15 15:54
Second Decision	2015-06-24 08:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-07-02 16:14
Articles in Press	2015-07-02 16:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-28 09:08
Publish the Manuscript Online	2015-08-21 13:37

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure
Manuscript Source	Invited Manuscript
All Author List	Marcello Maida, Massimo Iavarone, Maurizio Raineri, Calogero Cammà and Giuseppe Cabibbo
Funding Agency and Grant Number
Corresponding Author	Marcello Maida, MD, Section of Gas­troenterology, DIBIMIS, University of Palermo, P.zza delle Cliniche 2, 90127 Palermo, Italy. marcello.maida@unipa.it
Key Words	Systemic therapies; Sorafenib; Barcelona Clinic Liver Cancer; Hepatocellular carcinoma
Core Tip	Hepatocellular carcinoma (HCC) is the main cause of death in patients with cirrhosis with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Since then no other molecule has been registered as first-line therapy in this setting and one more vacuum arises from the absence of molecules registered as second-line therapy for patients who have failed Sorafenib. What are the reasons and what we should expect in the near future?
Publish Date	2015-08-21 13:37
Citation	Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057
URL	http://www.wjgnet.com/1948-5182/full/v7/i17/2053.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i17.2053

Full Article (PDF)	WJH-7-2053.pdf
Full Article (Word)	WJH-7-2053.doc
Manuscript File	17205-Review.docx
Answering Reviewers	17205-Answering reviewers.pdf
Audio Core Tip	17205-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17205-Conflict-of-interest statement.pdf
Copyright License Agreement	17205-Copyright assignment.pdf
Peer-review Report	17205-Peer-review(s).pdf
Scientific Misconduct Check	17205-Scientific misconduct check.pdf
Scientific Editor Work List	17205-Scientific editor work list.pdf